Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Finished Goods (2020 - 2021)

UroGen Pharma's Finished Goods history spans 2 years, with the latest figure at $888000.0 for Q1 2021.

  • For Q1 2021, Finished Goods changed N/A year-over-year to $888000.0; the TTM value through Mar 2021 reached $888000.0, changed N/A, while the annual FY2020 figure was $913000.0, N/A changed from the prior year.
  • Finished Goods reached $888000.0 in Q1 2021 per URGN's latest filing, down from $913000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $913000.0 in Q4 2020 to a low of $232000.0 in Q2 2020.